The clinical and laboratory characteristics of patients included in the study
| Parameter | Patients with PAPS, n = 52 |
|---|---|
| Average age, median [25; 75 percentiles], years | 38.5 [31.5; 43.5] |
| Duration of the disease, median [25; 75 percentiles], years | 9.0 [3.1; 13.0] |
| History of thrombosis, n (%) | |
| Arterial | 19 (37) |
| Venous | 23 (44) |
| Arterial + venous | 10 (19) |
| Recurrent thrombosis, n (%) | 34 (65) |
| Obstetric pathology*, n (%)/n | 18 (95)/19 |
| IgG аCL, n (%) | |
| by ELISA | 40 (77) |
| by CLA | 44 (85) |
| IgM аCL, n (%) | |
| by ELISA | 11 (21) |
| by CLA | 19 (36) |
| IgG anti-β2-GPI, n (%) | |
| by ELISA | 38 (73) |
| by CLA | 41 (80)/51 |
| IgМ anti-β2-GPI, n (%) | |
| by ELISA | 12 (23) |
| by CLA | 19 (36) |
| LA**, n (%)/n | 6 (75)/8 |
| IgA aCL by CLA, n (%)/N | 26 (53)/49 |
| IgA anti-β2-GPI by CLA, n (%)/N | 26 (53)/49 |
| IgG anti-β2-GPIDI by CLA, n (%)/N | 37 (77)/48 |
| AH, n (%) | 22 (42) |
| Hypercholesterolemia, n (%)/n | 1 (2)/46 |
| Active smoking, n (%) | 5 (10) |
| Type 2 diabetes mellitus, n (%) | 1 (2) |
| Obesity, n (%) | 15 (29) |
| Peri-operative, n (%) | 0 (0) |
| Hormonal contraception, n (%) | 0 (0) |
| Factor G20210A prothrombin (FII) mutation, n (%)/n | 2 (6)/32 |
| Factor V Leiden (FVL), n (%) | 0 (0)/32 |
| Therapy***, n (%) | |
| DOACs | 28 (54) |
| Warfarin | 12 (23) |
| LMWH | 4 (8) |
| Without anticoagulant therapy | 8 (15)**** |
| Low dose aspirin | 18 (35)***** |
| Hydroxychloroquine | 34 (65) |
*: obstetric pathology was calculated in women who had pregnancy in their disease course, in the numerator—“n” and “%” of women with obstetric pathology, in the denominator—“n” of women who had pregnancy in their disease course; numerator is the “n” and “%” of patients with positive aPLs, and denominator is the “n” of patients who had aPLs determination; **: LA study was performed in patients who have not taken anticoagulant therapy; ***: therapy at the time of inclusion in the study; ****: patients were diagnosed with APS for the first time, so they did not receive anticoagulant therapy before being included in the study; *****: five patients received aspirin in combination with anticoagulants, 13 patients received aspirin without anticoagulants. AH: arterial hypertension; CLA: chemiluminescent assay; DOACs: direct oral anticoagulants; ELISA: enzyme-linked immunoassay; LMWH: low-molecular-weight heparin; median [25; 75 percentiles]: median with interquartile range; n: number of patients